influenza vaccine (split virion, inactivated, H1N1)

This drug refers to a monovalent, inactivated, split-virion influenza vaccine specifically developed by **GSK** (GlaxoSmithKline Biologicals) to combat the 2009 H1N1 pandemic. The vaccine is produced by cultivating the influenza virus in embryonated chicken eggs, followed by inactivation with formaldehyde and disruption (splitting) of the virus particles using detergents like sodium deoxycholate. This process exposes the internal and surface antigens, primarily **hemagglutinin (HA)** and **neuraminidase (NA)**. GSK's formulations, notably **Pandemrix** and **Arepanrix**, were uniquely combined with the **AS03** adjuvant system (an oil-in-water emulsion containing squalene, DL-alpha-tocopherol, and polysorbate 80) to enhance the immune response and allow for dose-sparing. The vaccine works by inducing the production of neutralizing antibodies against the HA protein, thereby preventing the virus from attaching to and entering host cells.

Brand names

PandemrixArepanrix

Other names

influenza inactivated split virus strain A (H1N1)H1N1pdm09 vaccineH-1N1pdm09 vaccineH 1N1pdm09 vaccineA/H1N1 pandemic vaccine